Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms (Q34302770)

1 August 2017

title

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms (English)

1 reference

1 August 2017

James M Bogenberger

0 references

Raoul Tibes

1 reference

1 August 2017

Kasey L Benson

series ordinal

1 reference

1 August 2017

Ruben A Mesa

series ordinal

1 reference

1 August 2017

publication date

1 October 2012

1 reference

Molecular Diagnosis and Therapy

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

269-283

1 reference

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A long-term retrospective study of young women with essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Efficacy and safety of low-dose aspirin in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The haematocrit and platelet target in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

How I treat symptomatic splenomegaly in patients with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from five studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Melphalan treatment in patients with myelofibrosis with myeloid metaplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Palliative goals, patient selection, and perioperative platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with myeloid metaplasia at the Mayo Clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Outcome of transplantation for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Advances in understanding and management of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Identification of an acquired JAK2 mutation in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A gain-of-function mutation of JAK2 in myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

In vitro studies of human pluripotential hematopoietic progenitors in polycythemia vera. Direct evidence of stem cell involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Polycythemia vera blood burst-forming units-erythroid are hypersensitive to interleukin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The V617F JAK2 mutation is uncommon in cancers and in myeloid malignancies other than the classic myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis--impact on disease phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Clinical correlates of JAK2V617F allele burden in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK2 V617F mutation in essential thrombocythemia: correlation with clinical characteristics, response to therapy and long-term outcome in a cohort of 275 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

SOCS2: inhibitor of JAK2V617F-mediated signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The JAK2 exon 12 mutations: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutations in CBL occur frequently in juvenile myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

IDH mutation impairs histone demethylation and results in a block to cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Taxing sugar-sweetened beverages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Clinical effect of point mutations in myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

21 January 2018

12 December 2020

Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

EZH2 mutational status predicts poor survival in myelofibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Frequent pathway mutations of splicing machinery in myelodysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Assessing New Therapies and Their Overall Impact in Myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

The renaissance of interferon therapy for the treatment of myeloid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Evolution of clinical trial endpoints in chronic myeloid leukemia: efficacious therapies require sensitive monitoring techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40291-012-0006-3

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment

21 January 2018

1 reference

12 December 2020

Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

1 reference

12 December 2020

A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications

1 reference

12 December 2020

Blood consult: resistant and progressive essential thrombocythemia

1 reference

12 December 2020

Phase1/-2 study of Pomalidomide in myelofibrosis

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

DNMT3A mutations in myeloproliferative neoplasms

1 reference

12 December 2020

Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia

1 reference

12 December 2020

ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

1 reference

12 December 2020

Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia

1 reference

12 December 2020

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

12 December 2020

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

1 reference

12 December 2020

A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms

1 reference

12 December 2020

Danazol treatment of idiopathic myelofibrosis with severe anemia

1 reference

12 December 2020

Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms

1 reference

12 December 2020

Treatment of anemia in myeloproliferative disorders: a randomized study of fluoxymesterone v transfusions only

1 reference

12 December 2020

Reversal of myelofibrosis by hydroxyurea

1 reference

12 December 2020

10.1007/S40291-012-0006-3

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1009473398

0 references

1 reference